Headache and Migraine

Originally approved in 1996, the therapy, indicated for the treatment of to partial-onset and tonic clonic seizures, is now available in a liquid formulation.

Forget what you think you know about red wine or chocolate ‘activating’ migraine. Many commonly accepted “triggers” aren’t triggers at all.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending November 6, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 5, 2021.

Expert clinicians offer their perspectives on the ongoing shortage of neurologists, stigmas associated with migraine, diets for those with epilepsy, mesenchymal stem cells in MS, and other topics.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Investigators interviewed 20 community neurologists about the impact of the pandemic on their professional and personal lives, finding 4 main themes among their responses.

Here's what is coming soon to NeurologyLive.

Vocal cord edema, which was observed in 100% of patients with cluster headache, should continue to be explored in research settings, according to the study authors.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 29, 2021.

Proper diagnosis and effective treatment planning can drastically improve quality of life for individuals with migraine.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 23, 2021. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 22, 2021.

William B. Young, MD, codirector of Inpatient Program at Jefferson Headache Center, discussed how the clinical and patient communities can squash misguided migraine stigmas.

The headache specialist at Jefferson Headache Center discussed the need to revamp the education process for migraine care and how much time residents spend learning about the disease. [WATCH TIME: 2 minutes]

Two hours post-treatment with the remote electrical neuromodulation device resulted in the improvement of nausea, photophobia, phonophobia, and functional ability.

The primary pharmaceutical options suggested by national guidelines were considered effective by only 13.8% and 14.9% of the patients with persistent idiopathic facial pain.

Here's what is coming soon to NeurologyLive.

Roderick Spears, MD, FAHS, FAAN, professor of neurology, University of Pennsylvania, discussed the need to raise awareness of migraine and how the community can build upon the progress made.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 15, 2021.

The headache specialist at Jefferson Headache Center discussed the array of issues patients with migraine face and why her personal experience may resonate with patients. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive.

The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]